PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

Author：            

Publisher： Spandidos Publications

E-ISSN： 1791-2423|48|1|253-260

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.48, Iss.1, 2016-01, pp. : 253-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells

By            

Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. : 503-508

Spandidos Publications

Access to resources Recommend Favorite

Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation

By      

Oncology Reports, Vol. 29, Iss. 1, 2013-01 ,pp. : 380-386

Spandidos Publications

Access to resources Recommend Favorite

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

By        

International Journal of Oncology, Vol. 43, Iss. 5, 2013-01 ,pp. : 1627-1635

Spandidos Publications

Access to resources Recommend Favorite

Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model

By                

International Journal of Oncology, Vol. 47, Iss. 1, 2015-01 ,pp. : 377-383

Spandidos Publications

Access to resources Recommend Favorite